Beyfortus: Who Is It Recommended For?
News Context
At a glance
- The resurgence of VRS is a significant public health concern, notably given its impact on vulnerable populations. The availability of Nirsévimab represents a proactive step in mitigating severe...
- At-Risk Groups: Premature infants, infants under 2 years (especially
Respiratory Syncytial Virus (VRS) – At a Glance
- What: A common and contagious upper respiratory tract infection caused by the Respiratory Syncytial Virus (VRS).
- Where: Belgium (data focuses on Belgian cases), globally widespread.
- when: VRS season begins October 1st.
- Why it Matters: While generally mild, VRS poses a notable threat to infants, the elderly, and individuals with underlying health conditions, leading to hospitalizations and even death.
- What’s Next: Sciensano recommends Nirsévimab (Beyfortus) – a preventative antibody – for infants born between February 19th and October 1st. increased parental awareness and uptake of preventative measures are crucial.
VRS Statistics in Belgium
| Statistic | Value |
|---|---|
| Children under 5 contracting VRS annually | ~14,500 |
| Hospitalizations due to VRS (children under 5) | >3,000 |
| Global infant deaths due to VRS annually | 100,000 |
| Hospitalization reduction with Beyfortus (last year) | ~4,000 fewer hospitalizations |
| Hospitalization reduction percentage with Beyfortus (last year) | ~40% |
At-Risk Groups: Premature infants, infants under 2 years (especially <6 months), the elderly, and individuals with pulmonary/cardiac conditions, obesity, diabetes, chronic kidney disease, or weakened immune systems.